Universal Immunization to Fortify Immunotherapy Efficacy and Response

Although immune checkpoint inhibitors (ICIs) have substantially extended survival in many patients, most patients do not achieve durable responses on these treatments. There is a substantial unmet need for methods to sensitize more patients to ICIs. Studies have shown that personalized mRNA lipid nanoparticle vaccines enhance antitumor immunity in combination with PD1 inhibition, under the assumption that these vaccines generate T cells reactive against the targets encoded by the mRNA in the vaccines. However, it was recently found that mRNA vaccines targeting non-tumor antigens are also power

Trial Details

NCT ID
NCT07597070
Phase
PHASE2
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pfizer-BioNTech mRNA COVID-19 vaccine
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483

Key Eligibility Criteria

  • Adults ≥ 18 years of age.
  • Histologically or cytologically confirmed stage IV non-small cell lung cancer (NSCLC), defined as: adenocarcinoma, squamous cell carcinoma, large c…
  • ECOG Performance Status of 0 to 2.
  • Willing to receive Pfizer-BioNTech mRNA COVID-19 vaccine (for vaccine arms).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →